New humira copycat under the microscope: will it match up?

NCT ID NCT07181694

Completed Knowledge-focused Sponsor: Biocad Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study tests a new biosimilar drug called BCD-057, which is a copy of the arthritis medication Humira. It will involve 444 healthy men aged 18-45 who receive a single injection of either BCD-057 or Humira. The goal is to see if the body processes the two drugs similarly and to check for any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adalimumab (a biosimilar version of the drug Humira)
What this could lead to: If successful, this could show that BCD-057 works similarly to Humira, potentially offering a more affordable treatment option for inflammatory conditions.
What could go wrong: This is an early Phase 1 study in healthy volunteers, not patients. It only tests a single dose, so it cannot predict long-term safety or effectiveness in treating disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT MALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT MALE

Contacts and locations

Locations

I.M. Sechenov First Moscow State Medical University

Moscow, 119435, Russia
LLC "Research Center Eco-Safety"

Saint Petersburg, 196143, Russia
LLC "X7 Clinical Research"

Saint Petersburg, 194156, Russia
LLC "X7 Clinical Research"

Saint Petersburg, 199178, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.